Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P02545: Variant p.Glu161Lys

Prelamin-A/C
Gene: LMNA
Feedback?
Variant information Variant position: help 161 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Glutamate (E) to Lysine (K) at position 161 (E161K, p.Glu161Lys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and acidic (E) to large size and basic (K) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CMD1A. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 161 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 664 The length of the canonical sequence.
Location on the sequence: help LNSKEAALSTALSEKRTLEG E LHDLRGQVAKLEAALGEAKK The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         LNSKEAALSTALSEKRTLEGELHDLRGQVAKLEAALGEAKK

Mouse                         LNSKEAALSTALSEKRTLEGELHDLRGQVAKLEAALGEAKK

Rat                           LNSKEAALSTALSEKRTLEGELHDLRGQVAKLEAALGEAKK

Pig                           LNSKEAALSTALSEKRTLEGELHDLRGQVAKLEAALGEAKK

Chicken                       LNSKEAALSTALGEKRNLENEVRDLRAQVAKLEGALSEAKK

Xenopus laevis                LNSKDAALTTALGEKRNLENEIRELKAHIAKLEASLADTKK
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 661 Prelamin-A/C
Chain 1 – 646 Lamin-A/C
Domain 31 – 387 IF rod
Region 81 – 218 Coil 1B
Modified residue 144 – 144 N6-acetyllysine
Modified residue 155 – 155 N6-acetyllysine
Modified residue 171 – 171 N6-acetyllysine; alternate
Modified residue 171 – 171 N6-succinyllysine; alternate
Modified residue 180 – 180 N6-acetyllysine
Cross 171 – 171 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate



Literature citations
Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations.
Sebillon P.; Bouchier C.; Bidot L.D.; Bonne G.; Ahamed K.; Charron P.; Drouin-Garraud V.; Millaire A.; Desrumeaux G.; Benaiche A.; Charniot J.-C.; Schwartz K.; Villard E.; Komajda M.;
J. Med. Genet. 40:560-567(2003)
Cited for: VARIANT CMD1A LYS-161; Clinical and mutational spectrum in a cohort of 105 unrelated patients with dilated cardiomyopathy.
Millat G.; Bouvagnet P.; Chevalier P.; Sebbag L.; Dulac A.; Dauphin C.; Jouk P.S.; Delrue M.A.; Thambo J.B.; Le Metayer P.; Seronde M.F.; Faivre L.; Eicher J.C.; Rousson R.;
Eur. J. Med. Genet. 54:E570-E575(2011)
Cited for: VARIANTS CMD1A PHE-92; LYS-161; LYS-317 AND ARG-523;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.